NASDAQ$NVAX

Novavax Inc · Q2 2022 earnings

Q2 2022 earnings · · Investor relations

Briefing

Announced financial results and operational highlights for the second quarter ended June 30, 2022.

Novavax reported its Q2 2022 financial results, highlighting the delivery of its vaccine to the U.S. market and global distribution with over 23 million doses delivered since the start of Q3.

  • Delivered vaccine to the U.S. market with immunizations underway.
  • Distributed over 23 million doses globally since the start of the third quarter.
  • Gained positive momentum moving into the remainder of 2022 and into 2023.
  • Confident that the vaccine will play an important role in the long-term COVID-19 landscape through continued expansions to the label for adolescents and boosting and the vaccine’s competitive product profile.

Headline financials

Total Revenue

$186M

Previous: $298M-37.6%
EPS (adj)

-$6.53

Previous: -$4.75-37.5%
Free Cash Flow

-$510M

Previous: -$352M-44.9%
Net Income

-$510M

Previous: -$352M-44.9%
Operating Income

-$483M

Previous: -$346M-39.7%
Gross Profit

-$85.2M

Previous: $298M-128.6%
Cash & Equivalents

$1.38B

Previous: $2.07B-33.7%
Total Assets

$2.62B

Previous: $2.75B-4.6%
Stock-Based Comp

$38M

Previous: $53.1M-28.4%

Revenue & EPS history

Novavax · Revenue · Quarterly

$186M

Q2 2022-37.6%vs Q2 2021
Beat estimate in 7 of 15 quarters(47%)
ActualEstimate

Revenue by segment

Novavax · $2.23M total across 1 segment · Q3 2023

  • Product sales
    $2.23M

Forward guidance

Novavax is revising full year 2022 total revenue guidance to $2 to $2.3 billion. Total revenue reflects all sources, including product sales of Nuvaxovid by Novavax, grants revenue, royalties and other revenue.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2022

Historical avgQ2 2022

+2.5%

Avg return

Earnings day

+5.0%

Avg return

5 days after

+11.8%

Avg return

30 days after

36%

23 / 64 earnings

Positive

+193.3%

Q1 2024

Best reaction

-33.2%

Q2 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+15.6%+17.3%+17.0%
Q4 2025+0.5%-0.4%-11.3%
Q3 2025-3.0%-3.3%-10.1%
Q1 2025+11.6%+4.0%+25.2%
Q4 2024-3.6%+4.9%-4.4%
Q3 2024-13.8%-18.8%+0.1%
Q2 2024+8.3%+13.5%+8.6%
Q1 2024+193.3%+188.6%+306.5%
Q4 2023-17.9%-8.8%-20.6%
Q3 2023-8.2%-8.2%-18.1%
Q2 2023-5.3%-2.1%+21.7%
Q1 2023+20.7%+13.4%+3.2%
Q4 2022-20.9%-11.3%-24.0%
Q3 2022-4.1%+28.9%-10.9%
Q2 2022-33.2%-31.2%-49.2%
Q1 2022-6.0%-9.4%-12.5%
Q4 2021+2.6%-12.1%-8.4%
Q3 2021-18.4%-13.3%-17.8%
Q2 2021-15.2%+2.9%+12.4%
Q1 2021-21.5%-25.2%+19.1%
Q4 2020-10.9%-24.4%-21.6%
Q3 2020-12.4%+7.5%+28.2%
Q2 2020-12.2%-14.0%-46.7%
Q1 2020+112.6%+132.9%+140.0%
Q4 2019-12.8%-35.1%+60.1%
Q3 2019+3.8%-6.3%-1.6%
Q2 2019-8.2%-15.5%+15.5%
Q1 2019-7.8%-21.6%-44.3%
Q4 2018+7.8%+5.9%+3.9%
Q3 2018-3.7%-10.5%+7.3%
Q2 2018+22.5%+13.3%+24.2%
Q1 2018-1.2%+4.3%-1.2%
Q4 2017-4.2%-2.8%-15.3%
Q3 2017+0.9%+0.0%+24.8%
Q2 2017+3.1%+4.2%+22.9%
Q1 2017+14.9%+35.1%+43.2%
Q4 2016+9.4%+6.5%-7.2%
Q3 2016-3.4%-6.9%+0.7%
Q2 2016-9.2%-6.4%-0.3%
Q1 2016-8.9%
Q4 2015-0.2%
Q3 2015-12.2%
Q2 2015+28.3%
Q1 2015+4.4%
Q4 2014-1.9%
Q3 2014-7.2%
Q2 2014-5.0%
Q1 2014-7.1%
Q4 2013-0.8%
Q3 2013+3.2%
Q2 2013-10.8%
Q1 2013-8.9%
Q4 2012-0.5%
Q3 2012-1.8%
Q2 2012+0.5%
Q1 2012-5.7%
Q4 2011+0.0%
Q3 2011+0.0%
Q2 2011+5.9%
Q1 2011+0.4%
Q4 2010+0.0%
Q3 2010+1.3%
Q2 2010-1.3%
Q1 2010+14.9%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro